



December 9, 2016

## **Flexion Therapeutics to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference**

BURLINGTON, Mass., Dec. 09, 2016 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will provide a company overview at the BMO Capital Markets Prescriptions for Success Healthcare Conference on Wednesday, December 14, 2016 at 8:30 a.m. Eastern Time at the InterContinental New York Barclay Hotel in New York.

To access the live webcast and subsequent archived recordings for the presentation, please visit the Flexion website at <http://flexiontherapeutics.com/>.

### **About Flexion Therapeutics**

Flexion is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA). The company's lead product candidate, Zilretta™ (FX006) is being investigated for its potential to provide improved analgesic therapy for the millions of U.S. patients who receive intra-articular injections for knee OA pain annually.

#### Media Contact:

Danielle Lewis  
Lazar Partners  
T: 212-867-1768  
[flexionpr@lazarpartners.com](mailto:flexionpr@lazarpartners.com)

#### Investor Contact:

David Carey  
Lazar Partners  
T: 212-867-1768  
[dcarey@lazarpartners.com](mailto:dcarey@lazarpartners.com)

#### Corporate Contacts:

Fred Driscoll  
Chief Financial Officer  
Flexion Therapeutics, Inc.  
T: 781-305-7763  
[fdriscoll@flexiontherapeutics.com](mailto:fdriscoll@flexiontherapeutics.com)

Scott Young  
Sr. Director, Corporate Communications & Investor Relations  
Flexion Therapeutics, Inc.  
T: 781-305-7194  
[syoung@flexiontherapeutics.com](mailto:syoung@flexiontherapeutics.com)